Biotech firms like Amgen Inc. (AMGN) and Regeneron Pharmaceuticals, Inc. (REGN) are pushing the boundaries of medicine - battling chronic diseases and reshaping patient care. Upstream Bio, Inc. (UPB), a rising star in this niche, is making waves by focusing on severe respiratory and inflammatory disorders. Founded in 2021, the clinical-stage biotech firm has drawn major attention since its stock started trading on the Nasdaq on Oct. 11, signaling its drive to revolutionize treatments for unmet medical needs.
Now, the company is poised for another milestone, with UPB joining the Russell 2000 Index (RUT) at the market open on Monday, Dec. 23, potentially boosting its visibility and liquidity. Inclusion in this widely followed small-cap benchmark could attract fresh capital and continue to drive the stock’s momentum.
